Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic EGFR-mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by a heterogeneous array of resistance mechanisms. Activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilgucki, Molly, Yeung, Vincent, Ho, Grace, Bravo Montenegro, Gabriela L., Jones, Greg, Reuss, Joshua E., Liu, Stephen V., Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516460/
https://www.ncbi.nlm.nih.gov/pubmed/36188633
http://dx.doi.org/10.1016/j.jtocrr.2022.100396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516460/
https://www.ncbi.nlm.nih.gov/pubmed/36188633
http://dx.doi.org/10.1016/j.jtocrr.2022.100396

Ejemplares similares